Disclaimer and Compensation Disclosure

Last updated September 8, 2026

Section 17(b) compensation disclosure

Section 17(b) of the Securities Act of 1933 requires anyone who publishes material describing a security for compensation to disclose who paid them and how much. For the profile currently published on this website:

The compensation figure and campaign dates stated on any individual profile page govern for that page. If the engagement is extended or amended, this page and the page footers are updated together.

We are not licensed, and this is not advice

Neither Darrow Group LLC nor any of its members, officers, directors, contractors or employees is a licensed broker-dealer, account representative, market maker, investment banker, investment adviser, analyst or underwriter. Nothing published here is investment advice or a recommendation that any security is suitable for any particular person. Always consult a licensed securities professional before buying or selling.

Risk

Investing in the securities of the companies profiled or discussed here is suitable only for people who can tolerate a high degree of risk. Micro-capitalisation securities are highly speculative, may be thinly traded, and may be subject to significant price volatility. It is possible that a reader's entire investment could be lost. Never invest money you cannot afford to lose entirely.

Company-specific risk

VolitionRx Limited is an earlier-stage, pre-profit diagnostics company that has historically incurred operating losses and negative cash flow, has expressed substantial doubt about its ability to continue as a going concern, and expects to require additional capital that may be raised through equity or debt financings that could be dilutive to existing shareholders. The Company has outstanding convertible notes and other obligations that may result in additional dilution. As a micro-cap NYSE American–listed security, VNRX shares may be thinly traded, subject to significant price volatility, and exposed to listing-compliance, regulatory, clinical, commercial and competitive risks. Forward-looking milestones, licensing discussions, reimbursement submissions and trial or publication timelines may be delayed, may not occur, and may not produce the outcomes described.

Product and regulatory status

Nu.Q® NETs is CE-marked for sale in Europe. It is not FDA-cleared or FDA-approved in the United States. Any finger-prick lateral-flow format described in our material is an early-stage prototype, not a commercially available product. References to hospital “evaluations” mean evaluations, which may or may not convert to purchase agreements. Published studies cited regarding sepsis outcomes are observational research about clinical practice generally; none of them studied a VolitionRx product, and nothing we publish should be read as a claim that any VolitionRx product has been shown to improve survival or patient outcomes.

Forward-looking statements

Our material contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results could differ materially from those described. See the Terms of Use for the full statement.

Sources, and where to check them

Facts are drawn from public sources and cited so that you can verify them independently. Review the company's own filings and disclosure documents at www.sec.gov before making any investment decision. The SEC's investor-education website is www.investor.gov, and FINRA publishes guidance at finra.org/investors.

No performance claims

We make no price predictions and no claim that anything we publish will affect the price of any security. Past performance does not guarantee future results.